Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer

Frontiers in Oncology

Bashir Al Hussein Al Awamlh¹  Jim C. Hu¹  Christopher E. Barbieri¹  Michael Tzeng¹  Siv Venkat¹  Spyridon P. Basourakos¹  Patrick J. Lewicki¹  Jonathan E. Shoag²  Krishnan Patel⁴  Michael A. Gorin⁵ 

[1] Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, United States;Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States;Department of Urology, University of Pittsburg School of Medicine, Pittsburgh, PA, United States;Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, United States;Urology Associates and UPMC Western Maryland, Cumberland, MD, United States;

关键词: prostate cancer;    tissue biomarker;    prognosis;    genetic marker;    decision making;   

DOI  :  10.3389/fonc.2021.676716

来源: DOAJ

【 摘 要 】

Risk stratification of men with clinically localized prostate cancer has historically relied on basic clinicopathologic parameters such as prostate specific antigen level, grade group, and clinical stage. However, prostate cancer often behaves in ways that cannot be accurately predicted by these parameters. Thus, recent efforts have focused on developing tissue-based genomic tests that provide greater insights into the risk of a given patient’s disease. Multiple tests are now commercially available and provide additional prognostic information at various stages of the care pathway for prostate cancer. Indeed, early evidence suggests that these assays may have a significant impact on patient and physician decision-making. However, the impact of these tests on oncologic outcomes remains less clear. In this review, we highlight recent advances in the use of tissue-based biomarkers in the treatment of prostate cancer and identify the existing evidence supporting their clinical use.

【 授权许可】

Unknown